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Abstract 
Background and aims Tsumura-Suzuki obese diabetic (TSOD) is a good model of metabolic syndrome 
showing typical lesions found in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, and develops 
spontaneous hepatic tumors with a high frequency. Majority of the developing tumors overexpress glutamine 
synthetase (GS), which is used as a marker of hepatocellular carcinoma (HCC). The aim of this study is to 
assess the status of expression of metabolism-related genes and the level of bile acids in the TSOD 
mice-derived tumors and to determine the association with metabolic dysregulation between human HCC and 
TSOD mice-derived tumors. 
Methods GS-positive hepatic tumors or adjacent normal tissues from71-week-old male TSOD mice were 
subjected to immunohistochemical staining (IHC), quantitative RT-PCR (qRT-PCR), quantitation of cholic 
acid and taurocolic acid.  
Results We found that downregulation of the rate-limiting enzyme for betaine synthesis (BADH), at both 
mRNA and protein levels in GS-positive TSOD mice-derived tumors. Furthermore, the bile acid receptor FXR 
and the bile acid excretion pump BSEP (Abcb11) were found to be downregulated, whereas BAAT and 
Akr1c14, involved in primary bile acid synthesis and bile acid conjugation, were found to be upregulated at 
mRNA level in GS-positive TSOD mice-derived tumors. BAAT and Akr1c14 was also overexpressed at 
protein levels. Total cholic acid was found to be increased in GS-positive TSOD mice-derived tumors.  
Conclusion Our results strongly support the significance of TSOD mice as a model of spontaneously 
developing HCC. 
Keywords TSOD mice ‧ HCC ‧ Tumor metabolism ‧ Bile acid ‧ Spontaneous tumorigenesis model 
Abbreviations 
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4 
 
Introduction 
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is one of the major causes of 
cancer-related deaths worldwide [1]. The curative ratio of HCC is generally low because of asymptomatic 
features in the initial stage and a high rate of recurrence. Molecular and clinical studies are now being 
increasingly carried out for developing more effective strategies for HCC therapy. The outcomes of such 
studies have resulted in a useful concept, the so-called molecular targeting therapy. A multikinase-inhibitor, 
sorafenib, that inhibits the RAF family kinases, the vascular endothelial growth factor receptors, and the 
platelet-derived growth factor receptor-β, has now beenapproved for treating patients with progressive HCC 
[2]. Following comprehensive genome and proteome studies, the metabolomic strategy has been now 
highlighted for understanding the systemic alteration of metabolism by several diseases, including cancer. 
Recent advancements in metabolome analysis methods, have now revealed the drastic changes occurring in 
various types of cancer tissues, including HCC [3-5]. The metabolic syndrome, defined as a group of metabolic 
disorders that cause cardiovascular diseases and type 2 diabetes mellitus, is also regarded as a risk factor for 
HCC as well as cirrhosis and infection by hepatitis B and C viruses [6].  
The Tsumura-Suzuki obese diabetic (TSOD) mouse model displays typical phenotypes of metabolic 
syndrome, type 2 diabetes mellitus accompanied by severe obesity, glycosuria, hyperglycemia, 
hyperinsulinemia, and significant increase of glutamic-oxaloacetic transaminase level [7-10]. Old-aged (above 
4 months of age) TSOD mice also exhibit several markers of nonalcoholic fatty liver disease (NAFLD) and 
nonalcoholic steatohepatitis (NASH), and finally, develop spontaneous hepatic tumors at 10 months of age [11]. 
Our previous studies have shown that glutamine synthetase (GS), which is one of the markers of human HCC, 
is also expressed in hepatic tumors of TSOD mice and that GS-positive hepatic tumors of TSOD mice and 
human HCC exhibit similar histopathological characteristics [12]. In this study, we assessed the status of 
expression of metabolism-related genes and the level of bile acid in the liver of TSOD mice to determine the 
association with metabolic dysregulation between human HCC and hepatic tumors of TSOD mice. 
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Materials and methods 
TSOD mice and sample preparation 
Under specific pathogen-free condition, male TSOD mice (n = 10) were maintained with MF basal diet 
(Oriental Yeast, Tokyo, Japan) and chlorinated tap water ad libitum at the Institute for Animal Reproduction 
(Kasumigaura, Ibaraki, Japan). The breeding procedure was performed in accordance with the animal 
experiment guidelines specified by the Institute for Animal Reproduction. At 71 weeks of age, mice were 
euthanized with excess carbon dioxide, and their livers were excised for further analyses. The excised livers 
were cut at macroscopic-visible tumors, and one part of the livers were fixed in 10% neutral-buffered formalin, 
and the remaining part was frozen with liquid nitrogen. After determining the liver samples bearing 
GS-positive tumors by IHC, total RNA (in tumor lesions and normal tissue) was isolated from the frozen livers 
using RNeasy Mini kit (Qiagen, Valencia, CA, USA). In parallel, samples were also prepared for quantitation 
of bile acid. 
Immunohistochemical staining  
Formalin-fixed tissues from TSOD mice liver were embedded in paraffin and sectioned at a thickness of 4 µm. 
All sections were subjected to H&E staining and IHC. Rabbit polyclonal anti-GS (Clone GS-6; dilution 1:500; 
Millipore, CA, USA), anti-betaine-aldehyde dehydrogenase (BADH) (1:100; Abcam, Cambridge, UK), anti- 
bile acid-CoA amino acid acyltransferase (BAAT) (1:200; Abcam), and anti-3α-hydroxysteroid dehydrogenase 
(Akr1c14) (1:200; Abcam) were used as the primary antibodies. The sections were incubated with the primary 
antibodies in a wet chamber for 60 min at room temperature. After rinsing with Tris-buffered saline containing 
0.1% Tween 20, visualization was completed using a ChemMate ENVISION kit/horseradish peroxidase (Dako, 
Tokyo, Japan) following manufacturer’s protocol. All sections were counterstained with Mayer’s hematoxylin 
(Muto Pure Chemicals, Tokyo, Japan). 
Gene expression analysis  
The mRNA expression levels of GS, Gpc-3, choline dehydrogenase (CHD), BADH, betaine-homocysteine 
6 
 
methyltransferase (BHMT), carnitine O-acetyltransferase (CRAT), ∆9-desaturase (∆-9D), ∆6-desaturase 
(∆-6D), BAAT, Akr1c14, oxysterol-7α-hydroxylase (CYP7B1), cholesterol-7α-hydroxylase (CYP7A1), bile 
salt export pump (BSEP), and farnesoid X receptor (FXR) were assessed by qRT-PCR. Using RNAs (1 
µg/sample), complementary DNAs were synthesized by SuperScript II reverse transcriptase with a random 
hexamer (Life Technologies, Carlsbad, CA, USA). PCR experiments were carried out using SYBR Premix EX 
Taq II (Takara, Shiga, Japan) and STEP One real-time PCR system (Applied Biosystems, Carlsbad, CA, USA) 
according to the manufacturer’s protocol. The primer sequences are listed in Table 1. The relative mRNA 
expression levels were calculated using mouse β-actin as an internal control. 
Liquid chromatography/electrospray ionization-mass spectrometry (LC/ESI-MS)  
The levels of cholic acid and taurocolic acid from tumor lesion and normal tissue were quantitated using 
LC/ESI-MS, for which the method of sample preparation described by Hagio et al [13] was followed. Briefly, 
the tissues were homogenized in ethanol using a homogenizer. The obtained suspension was centrifuged to 
remove the insoluble materials. The supernatant was analyzed using LC-MS. LC was performed using an 
HPLC system (Infinity 1260, Agilent Technologies, Santa Clara, CA, USA) consisting of a binary pump, a 
degasser, an autosampler, and a thermostated column oven. An ODS column (Cosmocore, 2.1 × 100 mm, i.d., 
2.6 µm, Nacalai Tesque, Kyoto, Japan) was used for separation. Solvent A was acetonitrile-water (20:80) 
containing 10 mM ammonium acetate. Solvent B was acetonitrile-water (80:20) containing 10 mM 
ammonium acetate at a flow rate of 0.4 mL/min; 0-5 min, 5% B, 5-15 min, 5%-15% B, 15-20 min, 15%-25% 
B; 20-22 min, 25%-75% B; and 22-24 min, 75% for wash. The MS system was used by Q-TOF MS (MaXis, 
Bruker Daltonik GmbH). The TOF spectra were acquired in negative ion detection mode. 
Statistical analysis  
All comparisons were performed using two-tailed Student’s t-tests, and the differences were considered 
statistically significant when P < 0.05. 
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RESULTS 
Since our previous report shows that TSNO mice, the control strain of TSOD mice, did not occur any hepatic 
tumors under same experimental period [11], we assessed changes of various parameters in GS-positive tumor 
lesions by comparing to those in adjacent normal hepatic tissues. An 80% (8/10) of mice carried one or more 
hepatic tumors that were visible macroscopically. No tumors were found in any other organs. We performed 
IHC for GS using all the tumor lesions and found that the majority of tumors (75%; 6/8) diffusely expressed 
GS (Fig. 1a). To validate whether GS overexpression also occurred at the mRNA level, we determined the 
relative mRNA level using qRT-PCR. As expected, GS mRNA levels in GS-positive tumor lesions were 
significantly higher than those in normal hepatic tissue. The levels of Gpc-3, known as a clinical marker of 
HCC, were also tested in GS-positive tumor lesions, which showed an increasing tendency, though not 
significant (Fig. 1b).  
Tissue metabolomics using human HCC have reported decreased levels of betaine, propionylcarnitine, 
C18:1 free fatty acid (FFA), and C16:1 FFA and increase levels of C18:3 FFA [14]. We tested the mRNA 
expression of enzymes responsible for their synthesis, anabolism, or conversion, as shown in Figure 2a. BADH, 
which directly synthesizes betaine from betaine aldehyde, was significantly downregulated in GS-positive 
tumor lesions compared to that in normal tissue, whereas CDH (synthetic enzyme for betaine aldehyde) and 
BHMT (anabolic enzyme of betaine) were not altered. IHC for BADH was also performed using paraffin 
sections of GS-positive and -negative tumors. Compared to that in the adjacent normal tissue, an obvious 
decrease in stainability was found only in GS-positive tumors (Fig. 2b). We performed IHC for 
4-hydroxy-2-nonenal (4-HNE), which is a typical product of oxidative stress of lipid. Regardless of GS 
positivity, all tumor lesions showed weak-positive finding, whereas normal tissue did not (data not shown). 
CRAT, which synthesizes propionylcarnitine from propionyl-CoA and L-carnitine, showed an increasing trend 
in GS-positive tumor lesions (P = 0.11). ∆-9D, which converts from C18:0 FFA and C16:0 FFA to C18:1 FFA 
and C16:1 FFA, respectively, also showed an increasing trend in GS-positive tumor lesions (P = 0.07). In 
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contrast, ∆-9D, which converts from C18:2 FFA to C18:3 FFA, showed a decreasing trend in GS-positive 
tumor lesions (P = 0.09, Fig. 2a). 
We next examined the mRNA expression of the enzymes and regulators that are involved in the synthesis 
and excretion of primary bile acid, as shown in Figure 3. BAAT and Akr1c14, which are ultimate bile acid 
synthetases, showed an increasing trend in GS-positive tumor lesions (P = 0.10 and P = 0.13, respectively). 
Consistent with the mRNA levels, the IHC staining revealed an apparent overexpression of BAAT and 
Akr1c14 only in GS-positive tumors (Fig. 3a). The levels of another ultimate bile acid synthetase, CYP7B1, 
were not altered. CYP7A1, which plays a pivotal role in bile acid intermediate synthesis, showed a decreasing 
trend in GS-positive tumor lesions (P = 0.15, Fig. 3a). An excretory transporter of bile acid, BSEP, and its 
positive regulator, FXR, were apparently downregulated in GS-positive tumor lesions (P < 0.01, Fig. 3b). The 
levels of primary bile acids in GS-positive tumors and normal tissue were also measured using LC/ESI-MS. 
The total level of colic acid (an aggregate of all types of isomers) was significantly increased in GS-positive 
tumors (P < 0.01), whereas a moderate increase in total taurocholic acid level was found in GS-positive tumors 
(P = 0.05, Fig. 3c). However intrahepatic bile acid was found in mice bearing GS-positive tumors, typical 
symptoms of cholestasis (jaundice and pruritus) were not observed at the time of sacrifice (data not shown). 
Using IHC for α-smooth muscle actin (α-SMA), we also tested numbers of stellate cells, which have been 
indicated an association between obesity-Gut microbiome, bile acid-induced their senescence, and HCC 
progression [15], however, numbers of α-SMA-positive cells were not altered between tumor lesions and 
normal tissues (data not shown). 
 
Discussion 
TSOD mice are established as an inbred strain from ddY mice [7] and have used as a model of metabolic 
syndrome and type 2 diabetes mellitus. At an early stage of lifespan (-4 month old), typical phenomena of 
obesity are first shown. After then, symptoms of type 2 diabetes (hyperglycemia and hyperinsulinemia) and 
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pathological changes in liver (manifestations of NAFLD/NASH; namely sporadic hepatocellular ballooning, 
Mallory-Denk bodies, and mild lobular inflammation) begin to appear and hepatic tumors finally develop [16]. 
Hirayama et al [17] have attempted to genetic analysis of this strain and identified genetic loci to exhibit 
phenomena of type 2 diabetes. However, genes responsible for these pathological findings including hepatic 
tumorigenesis has not been identified yet. Various animal models of carcinogenesis in liver have been 
established using chemical carcinogens or genetic manipulation [18-21]; however, a spontaneous model of 
HCC is less known. The only reported model is the C3H/HeNCrj strain that develops liver tumors in 26% of 
mice at the age of 16-months [22]. Similar to this strain, we found that the TSOD strain develops spontaneous 
hepatic tumors with a high rate at 10 months of age. Our previous report also showed that the histopathological 
features of TSOD-derived hepatic tumors are similar to those of human HCC, including the expression pattern 
of the clinical marker GS [12]. To clarify whether the expression pattern of molecules responsible for the 
alteration of metabolism and bile acid synthesis/excretion in human HCC is altered, we conducted quantitative 
analyses of gene expression and primary bile acids, as well as immunohistochemical examinations. Similar to 
our previous report, 71-week old TSOD mice developed hepatic tumors with a high rate and with a high 
frequency of GS expression. Although TSOD mice are also displays typical phenotypes of NASH at 4 months 
of age [11, 16], we could not find any severe steatosis, fibrosis, ballooning and inflammation in non-tumor 
lesion of TSOD mice liver at 71-week old. Clinically, it is well known that hepatic fat loss are often found in 
patient with advanced NASH (called as burnt-out NASH). This similarity between TSOD mice-derived 
GS-positive tumors and human HCC may strengthen the utility of TSOD mice to analyze pathophysiological 
features during the NASH-HCC sequence. Compared with several NASH model reported previously [23-25], 
a remarkable point of TSOD mice is that tumorigenesis can be found under spontaneous condition with high 
incidence. It should be emphasized this feature if using TSOD mice as a model for NASH-HCC sequence. 
These GS-positive tumors also expressed Gpc-3 mRNA, which is used as another clinical marker for human 
HCC, with a moderately increasing trend. Unpredictably, when we attempted to detect Gpc-3 protein by IHC, 
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no staining patterns were found in all GS-positive- and -negative tumor lesions as well as in normal tissues 
(data not shown). This results suggests that post-transcriptional, translational, or post-translational regulations 
of Gpc-3 that affect the immunoreactivity to anti-Gpc-3 may occur in hepatic tumors from TSOD mice. To 
understand the biological role of Gpc-3 during tumorigenesis in this model, characteristics of Gpc-3 regulation 
in tumors should be clarified in future. These results suggest that the TSOD mice may be a more useful model 
of spontaneous HCC than are the C3H/HeNCrj mice because of the high incidence of tumorigenesis and GS 
and/or Gpc-3 expression levels.  
Currently, it is widely known that the metabolic features of cancer tissues, including HCC, are drastically 
altered compared to those of normal tissues [26, 27]. Hence, we next focused on this viewpoint and assessed 
the expression of enzymes that are responsible for the synthesis, anabolism, or conversion of betaine, 
propionylcarnitine, and FFA. Our results strongly suggested that betaine levels in GS-positive tumor tissue 
may decrease due to the downregulation of BADH, a synthetic enzyme of betaine. Since betaine has been 
reported to act as an anti-oxidant and an anti-inflammatory agent [28], down-regulation of BADH may be one 
of the causes of tumorigenesis in the TSOD mouse liver as well as in human HCC. Results of 4-HNE level 
also suggests that the oxidative stress may contribute to hepatic tumorigenesis in this model, but is not likely to 
play a role in HCC progression. The trends of ∆-9D and ∆-6D alterations also support that consequential 
changes of C18:1 FFA, C16:1 FFA, and C18:3 FFA are likely to occur in TSOD mice-derived GS-positive 
tumors as well as in human HCC. These results suggest that a similar alteration of metabolites emerges in both 
TSOD mice-derived GS-positive tumors and human HCC. 
Primary and secondary bile acids are indispensable digestive components; however, their excess exposure 
causes several diseases. In general, secondary bile acid has been believed to have carcinogenic activity [29]; 
however, intrahepatic bile acid (namely primary bile acid) has also been reported to be a stimulator of hepatic 
tumorigenesis [30, 31]. Therefore, we investigated the levels of enzymes and regulators that are involved in the 
synthesis and excretion of primary bile acid. As expected, the synthetic enzymes of primary bile acid, BAAT 
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and Akr1c14, in TSOD mice-derived GS-positive tumors were upregulated at both mRNA and protein levels. 
Moreover, IHC using paraffin sections from autopsy cases revealed an overexpression of BAAT and Akr1c14 
only in human HCC tissues (5/5, data not shown). In contrast, CYP7A1, BSEP, and FXR were downregulated. 
The net levels of total cholic acid and taurocholic acid were increased, in accordance with the 
above-mentioned results except for CYP7A1. These data strongly suggest that multiple genes expressions, 
which are associated with synthesis and secretion of bile acid, alters simultaneously in TSOD mice-derived 
GS-positive tumors and that an excess accumulation of primary bile acids in the hepatic tissue of TSOD mice 
as a net result, as well as in human HCC. Especially, since BSEP and FXR are reported to be downregulated in 
HCC [32, 33], the same molecular basis of bile acid secretion may have occurred. Irrespective of being 
primary or secondary, the common biological activity of bile acid is emulsification and solubilization of cell 
surface components as a surfactant. This activity probably leads to cellular damage in the tissue where the 
overload of bile acids occurs. Our results also suggests that an accumulation of primary bile acids may play a 
role both in tumorigenic and tumor-progressive stage by insulting hepatic cells in this model. The fact that we 
did not observed any symptoms of cholestasis in mice bearing GS-positive tumors may be explained that the 
degree of intracellular accumulation of bile acids in this model does not reach threshold to arise macroscopic 
findings of cholestasis. That is, our findings, the alterations of BAAT, Akr1c14, BSEP, FXR, and primary bile 
acid levels, may explain why TSOD mice specifically develop hepatic tumors as well as alteration of enzyme 
levels in betaine- and FFA-related metabolism.  
Altogether, these results suggest that the alteration of the metabolic pattern observed in human HCC also 
occur in GS-positive hepatic tumors of TSOD mice. Furthermore, an overloading of primary bile acid in the 
hepatic tissue was found. This observation indicates that the metabolic features of GS-positive hepatic tumors 
in TSOD mice resemble those of human HCC and that exposure of bile acid to hepatic tissue may be a trigger 
of tumorigenesis in TSOD mice. Our findings in this study are further evidence for using TSOD mice as a 
model of spontaneously occurring HCC. 
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Figure Legends 
Fig. 1 Hepatic tumors in TSOD mice. a Representative images of GS-positive and –negative tumor lesions in 
71-week old male TSOD mice. Dotted lines in the H&E section are borderlines between normal and tumor 
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lesions. T, tumor lesion. b The levels of GS and Gpc-3 in GS-positive tumors and adjacent normal liver tissue 
were determined using qRT-PCR. The relative expression levels were calculated using values of β-actin 
qRT-PCR as an internal standard. Columns, mean values (n = 6); bars, SD. * P <0.05 by Student’s t-test 
(compared to values in normal tissue). 
Fig. 2 mRNA and protein expression of enzymes that are responsible for the synthesis, anabolism, or 
conversion of betaine, propionylcarnitine, and FFA in GS-positive TSOD mice-derived hepatic tumors. a The 
levels of CHD, BADH, BHMT, CRAT, ∆-9D, and ∆-6D in GS-positive tumors and adjacent normal liver 
tissue were determined using qRT-PCR. The relative expression levels were calculated using values of β-actin 
qRT-PCR as an internal standard. Columns, mean values (n = 6); bars, SD. b GS-positive and -negative tumors, 
including the adjacent normal tissue, were subjected to IHC for BADH. N, normal tissue; T, tumor lesion. * P 
<0.05 by Student’s t-test (compared to values in normal tissue). 
Fig. 3 mRNA and protein expression of enzymes that are involved in the synthesis and excretion of primary 
bile acid in GS-positive TSOD mice-derived hepatic tumors. a The levels of BAAT, Akr1c14, CYP7A1, 
CYP7B1, and CYP8B1 in GS-positive tumors and adjacent normal liver tissue were determined using 
qRT-PCR. The relative expression levels were calculated using values of β-actin qRT-PCR as an internal 
standard. Columns, mean values (n = 6); bars, SD. In parallel, GS-positive and -negative tumors, including the 
adjacent normal tissue, were subjected to IHC for BAAT and Akr1c14. N, normal tissue; T, tumor lesion. b The 
levels of BSEP and FXR in GS-positive tumors and adjacent normal liver tissue were determined using 
qRT-PCR. The relative expression levels were calculated using values of β-actin qRT-PCR as an internal 
standard. Columns, mean values (n = 6); bars, SD. c Intrahepatic levels of total CA and total TCA in 
GS-positive tumors and adjacent normal liver tissue were determined using LC/ESI-MS. Columns, mean 
values (n = 4-5); bars, SD. ** P <0.01 by Student’s t-test (compared to values in normal tissue). 
 
 



Table 1 Primer sequences for qRT-PCR
Target Forward (5' to 3') Reverse (5' to 3')
mGS AACACCTTCCACCATGGCCA TGTCGCTGTTGGAGCCTTCA
mGpc3 AGGACTGTGGCCGTATGCTC TGCCTCCGTTCTTCTGCACA
mCHD GCGGCTCCTCATCCCTCAAT TGAAGCGGGTGGTTGGTCTT
mBADH AACCCACCATTGTGACCGGT CGTTCACGATGCCACAGTCG
mBHMT GCTACCATGTGCATTGGGCC TGTTTGCCACAGTCAGGGGT
mCRAT TCTCTAGCAAGGCCCCAACG TTTTGGCCTGGCTGTGGAGA
m∆-9D GCAAACACCCGGCTGTCAAA ATAGAGATGCGCGGCACTGT
m∆-6D CGGGACTGGCTGGATTCCTA CCATACTCAAGGGGCTGCCA
mBAAT CACACCACGTTCCTGAGGGT ACCTCACCCACTTCACTGGC
mAkr1c14 CTTCAGGCAGCTGGAGACGA TCAGGACCACAATTCCACGCT
mCYP7A1 GGAAAGGCTGGCTGAGAGCT TGGCATTCCCTCCAGAGCTG
mCYP7B1 CCCCCAAATGCAACCGCTAC AGGCACAGCTTTCTGGCAGA
mCYP8B1 TGAAGGCTGTGCGTGAGGAA AGCCACCTTATCTCCGCGAC
mBSEP CCTCATACGGAAACCCAAGATC CCTCATACGGAAACCCAAGATC
mFXR GGACGGGATGAGTGTGAAG TGAACTTGAGGAAACGGGAC
mβ-actin GGCTCCTAGCACCATGAAGA GTACTTGCGCTCAGGAGGAG
